Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endo Pharmaceuticals Inc.

Division of Endo International PLC
www.endo.com/endopharma/home

Latest From Endo Pharmaceuticals Inc.

Finance Watch: 3Q Biopharma Venture Capital Financings Fell From 2Q Spike

VC deals totaled $8.3bn in the first half of 2019, but the year's total rose to just $11.5bn at the end of September, reflecting only a $3.2bn third quarter gain. Among recent financings, Cygnal emerged from stealth mode with $65m invested to date.

Financing StartUps and SMEs

Endo’s Opana IR Should Not Add Pediatric Data To Labeling, US FDA Panel Says

Incorporating data from two studies that raised safety and efficacy concerns would give a false sense of security about the drug’s use in pediatric patients, the panel majority said, while dissenters said some pediatric data in labeling is better than no information at all.

Advisory Committees Pediatrics

Opana IR Pediatric Labeling Supplement Faces US FDA Panel Review

Endo seeks to add findings from two open-label pediatric studies to labeling for its immediate-release opioid analgesic but is not seeking a pediatric use indication; advisory committee also will consider whether something more than routine pediatric safety monitoring is needed for Purdue’s OxyContin, which added a pediatric indication in 2015.

Advisory Committees Pediatrics

Opioid Litigation Pushes American Pain Society Into Bankruptcy

Labeled by plaintiffs as a 'front group' for opioid makers, the organization was pulled into the multidistrict litigation in Ohio and filed for Chapter 7 bankruptcy in June. It ceased operations in July.

Legal Issues Policy
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gynecological, Urological
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Endo International PLC
  • Senior Management
  • Contact Info
  • Endo Pharmaceuticals Inc.
    Phone: (484) 216-0000
    1400 Atwater Dr.
    Malvern, PA 19355
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register